Calcitriol
- PMID: 30252281
- Bookshelf ID: NBK526025
Calcitriol
Excerpt
This activity provides an in-depth review of calcitriol, a hormonally active synthetic vitamin D analog prescribed to manage hypocalcemia and renal osteodystrophy. FDA-approved indications include treating hypocalcemia in patients undergoing chronic renal dialysis, secondary hyperparathyroidism in those with chronic kidney disease not yet requiring dialysis, and hypocalcemia in patients with hypoparathyroidism or pseudohypoparathyroidism. The activity examines the mechanism of action, administration routes, and pharmacokinetics of calcitriol, along with strategies for effective monitoring to optimize therapeutic outcomes.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT. Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83. - PubMed
-
- Dadkhah PA, Farshid A, Khademi R, Yaghoubi S, Asadzadeh A, Moharamnejad N, Jadidian F, Ziaei SA, Haghshoar S, Salimi O, Shafagh SG, Rabiei N, Shahsavari S, Shokravi S, Maroufi Z, Deravi N, Erabi G, Naziri M. Impact of oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy: Systematic review and meta-analysis. Scand J Surg. 2024 Dec;113(4):263-272. - PubMed
-
- Kravvas G, Gholam K. Use of topical therapies for pediatric psoriasis: A systematic review. Pediatr Dermatol. 2018 May;35(3):296-302. - PubMed
Publication types
LinkOut - more resources
Full Text Sources